3 Reasons to Buy AbbVie Stock Like There's No Tomorrow
💡 Key Takeaway
AbbVie's post-Humira recovery, driven by Skyrizi and Rinvoq, a deep pipeline including weight-loss and eczema drugs, and a strong dividend make it a compelling long-term buy.
What Happened: AbbVie's Post-Humira Strategy Pays Off
AbbVie's stock is up 10% year-to-date, slightly outperforming the S&P 500. Despite the patent loss of its former blockbuster Humira in 2023, the company quickly resumed revenue growth thanks to its immunology drugs Skyrizi and Rinvoq.
These two drugs are expected to generate over $31 billion in combined revenue this year, exceeding management's original 2027 target of $27 billion. They have successfully filled the gap left by Humira and face no biosimilar competition until at least 2033.
AbbVie is also investing in future growth. It is developing ABBV-295, a weight-loss therapy that showed promising early results, and recently acquired Apogee Therapeutics for $10.9 billion to gain zumilokibart, a potential eczema treatment with a convenient dosing schedule.
Additionally, AbbVie maintains a strong dividend, having increased payouts for over 50 consecutive years, making it a Dividend King. The forward yield of 2.7% is well above the S&P 500 average.
Why It Matters: AbbVie's Growth Drivers and Dividend Appeal
For investors, AbbVie's ability to rebound from Humira's patent loss demonstrates strong management and a diversified portfolio. The outperformance of Skyrizi and Rinvoq provides a solid revenue base for the next decade, reducing reliance on any single drug.
The pipeline, including weight-loss and eczema treatments, positions AbbVie for long-term growth in high-demand markets. The weight-loss market alone is projected to exceed $100 billion, offering significant upside if ABBV-295 succeeds.
AbbVie's dividend program is a key attraction for income-focused investors. With a 2.7% yield and consistent increases, it offers a reliable income stream that can enhance total returns over time.
However, risks remain. Humira sales continue to decline, and pricing pressure on Imbruvica from government negotiations could hurt revenue. Investors should monitor these headwinds, but the overall outlook is positive for those with a long-term horizon.
Source: The Motley Fool
Analysis generated by Bobby AI quantitative model, reviewed and edited by our research team. This is not financial advice. Always do your own research before making investment decisions.
Bobby Insight
AbbVie is a strong buy for long-term investors seeking growth and income.
AbbVie has successfully navigated the Humira patent cliff, with Skyrizi and Rinvoq driving robust revenue growth. Its pipeline, including weight-loss and eczema therapies, offers significant future potential. The dividend is reliable and growing, making it attractive for total return.
What This Means for Me
